CVS Caremark Adds VOQUEZNA Tablets To National Formularies For 26M Commercially Insured Members
Portfolio Pulse from Benzinga Newsdesk
CVS Caremark has added VOQUEZNA tablets, developed by Phathom Pharmaceuticals, to its national formularies, making it accessible to over 116 million commercially covered lives. This is the first FDA-approved PCAB for GERD treatment in over 30 years.
July 30, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CVS Caremark has added VOQUEZNA tablets to its national formularies, expanding access to over 116 million commercially covered lives. This move could enhance CVS's market position in the healthcare sector.
Adding a new FDA-approved treatment to its formularies can attract more customers and strengthen CVS's position in the healthcare market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Phathom Pharmaceuticals' VOQUEZNA tablets have been added to CVS Caremark's national formularies, making it the first FDA-approved PCAB for GERD treatment in over 30 years. This could significantly boost Phathom's market presence and revenue.
Being included in CVS Caremark's formularies can greatly increase the market reach and sales of VOQUEZNA, positively impacting Phathom Pharmaceuticals' financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90